Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes

Kim, Mi Jung; Ro, Jae Y.; Ahn, Sei Hyun; Kim, Hak Hee; Kim, Sung‐Bae; Gong, Gyungyub

doi:10.1016/j.humpath.2006.04.015

Cited by 294 publications

(343 citation statements)

References 35 publications

Supporting

Mentioning

246

Contrasting

Unclassified

Order By: Relevance

“…Inhibition of FABP7 expression in turn inhibits EGF-induced migration in glial cells, suggesting that EGFR induced invasion properties is partly mediated by FABP7 [48]. The link between FABP7 and EGFR is of interest in breast carcinomas, especially the basal-like group, as EGFR has been identified by several publications to be one of the discriminating factors of this particular group [51][52][53].…”

Section: Discussionmentioning

confidence: 99%

The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer

Zhang

Rakha

Ball

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

MethodsWe analysed 48,000 gene transcripts in 132 invasive breast carcinomas to identify two novel genes (OATP2 and FABP7) significantly associated with BP (defined by cytokeratin (CK)5/6 and/or CK14 positivity). Using a series of invasive breast carcinoma cases (n=899), prepared as tissue microarrays, we assessed OATP2 and FABP7 protein expression using immuncocytochemistry to investigate associations with clinicopathological variables, patients" outcome and ability to refine BP classification. ResultsA total of 7.9% and 15.6% cases were OATP2 and FABP7 positive respectively. OATP2 was associated with tumours of high histological grade (p<0.01), ER and PgR negativity (p<0.01) and shorter breast cancer specific survival (BCSS; p=0.04). FABP7 expression was associated with lower lymph node stage (p<0.01), ER and PgR negativity (p<0.01). BP tumours which were FABP7 positive had a significantly longer BCSS (p=0.05) and disease-free survival (DFS; p=0.01) compared with FABP7 negative basal tumours (p<0.01). OATP2 positive tumours were associated with adverse survival and increased risk of early recurrence. ConclusionsThis study confirms the biological and clinical heterogeneity of the BP in breast cancer. We have

show abstract

Section: Discussionmentioning

confidence: 99%

The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer

Zhang

Rakha

Ball

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…This variety of breast carcinoma was characterized by genetic studies and by immunohistochemical expression of basal cytokeratins, mainly types 5, 14 and 17, epidermal growth factor receptor (EGFR) and p53, [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] but results from diverse studies are not always concordant. Recently, 'pure' and 'myoepithelial' variants of basal breast carcinoma were described, based on S-100, actin or p63 expression.…”

mentioning

confidence: 99%

Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas)

et al. 2007

View full text Add to dashboard Cite

Basal breast carcinomas triple negative for estrogen receptors, progesterone receptors and Her2/neu breast carcinomas are more aggressive than conventional neoplasms. We studied 64 cases with immunohistochemistry, using 23 antibodies, to characterize diverse pathological pathways. A basal cytokeratin was identified in 81% of tumors and vimentin was identified in 55%. The mean Ki67 index was 46% (range, 10-90%). Coincident expression of p50 and p65, which suggests an active nuclear factor-jB factor, was present in 13% of neoplasms. Epithelial growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGF-IR) or c-kit (CD117) was identified in 77% of tumors. Loss of protein tyrosine phosphatase was found in 14%, whereas Akt activation was present in 28%. Several differences were identified between two subtypes of basal breast carcinomas: the pure variant (negative S-100 and actin) was more frequently associated with 'in situ carcinoma' (P ¼ 0.019) and pBad overexpression (P ¼ 0.098), whereas the myoepithelial variant (positive S-100 or actin) showed more frequent tumor necrosis (P ¼ 0.048), vimentin expression (P ¼ 0.0001), CD117 expression (P ¼ 0.001) and activated caspase-3 (P ¼ 0.089). IGF-IR could be as important as EGFR for the growth of these neoplasms. Basal cell carcinoma has at least two subtypes with distinct microscopic and immunohistochemical features.

show abstract

“…Triple negative tumours and ER-ve, PR-ve and HER2 + ve tumours are of worse prognosis among the different sub types [17,25,26]. A few studies even associated ER-ve, PR-ve and HER2 + ve sub types with worst prognosis among the different subtypes [27,28]. ER-ve, PR-ve and HER2 + ve tumours are also associated with increased risk of loco regional recurrence following breast conservation surgery [29].…”

Section: Follow Upmentioning

confidence: 99%

Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

Bhattacharjee

Bansal

Nepal

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Interleukin 10 (IL10) is a poor prognostic marker in several cancers. Its role in breast cancer is not well elucidated. The present study is designed to see the expression of IL10 in breast cancer tissue and to evaluate its correlation with the established markers of prognosis. Sixty female patients who underwent surgery for breast cancer were enrolled for the study. Immediately after surgery, 2-5 g of tumour tissue and similar volume of peritumoural normal breast tissue were collected for IL10 assay. IL10 expression was assayed by immunohistochemistry. IL10 expressing tumours and IL10 non expressing tumours were compared. Chi square/Fisher exact test and student's t test were used to compare the data. p-valueless than 0.05 was considered as statistically significant. Thirty six patients (60 %) of carcinoma breast showed IL 10 expression in tumour tissue as compared to no IL 10 expression in any peritumouralnormal breast tissue (p < 0.01). IL10 expression had statistically significant correlation with locally advanced disease, tumour grade, HER2 + ve tumours and ER-ve, PR-ve, HER2 + ve breast cancer subtypes (p = 0.001, 0.001, 0.001 and 0.01 respectively). No correlation could be found with patient's age, tumour size, tumour histology and ER and PR status. Correlation of IL10 expressing tumours with several established poor prognostic markers of breast cancer may indicate the possible association of IL10 expression with poor prognosis. Large studies with long term follow up are needed to substantiate the association of IL10 with poor prognosis.

show abstract

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes

Cited by 294 publications

References 35 publications

The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer

The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer

Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas)

Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

Contact Info

Product

Resources

About